Evidence. Phase 2a RCT (n=65, T2D on metformin, 1,000 mg/day × 28 d): improved glucose handling, blood pressure and 6-min walk distance; 2026 phase 1b (n=23, obesity/prediabetes, 400 mg/day × 8 wk): lower liver and visceral fat, higher resting energy expenditure. Consumer capsules standardize to 100 mg; typical use 100–300 mg/day in 8–12 week cycles.
Cautions. Investigational compound — no long-term human safety data; may add to glucose-lowering medication (monitor); cycle 8–12 weeks on / equal time off; not in pregnancy or nursing.
pubmed.ncbi.nlm.nih.gov/?term=O304+AMPK+a…peptidelibrary.app/library/atx-304biolongevitysupplements.com/product/bioamp/




















